Kogrel

Clopidogrel, the active ingredient in Kogrel, is an antiplatelet agent presented as an oral tablet for oral use. It is employed to reduce atherothrombotic events in patients who have experienced myocardial infarction, stroke, or have established peripheral arterial disease. GNH USA supplies Kogrel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kogrel, a P2Y12 receptor antagonist, is used in several cardiovascular conditions to inhibit platelet aggregation.

Recent myocardial infarction: lowers risk of recurrent heart attacks and cardiovascular death. Ischemic stroke: reduces chance of subsequent stroke events. Peripheral arterial disease: helps prevent limb‑related atherothrombotic complications. Acute coronary syndrome: provides early antiplatelet protection. Post‑percutaneous coronary intervention (PCI): maintains vessel patency and reduces stent thrombosis.

Adverse reactions to clopidogrel may vary in frequency and severity.

Common Side Effects: - Bleeding gums - Easy bruising - Nausea - Diarrhea

Serious or Rare Side Effects: - Severe intracranial or gastrointestinal bleeding - Thrombotic thrombocytopenic purpura - Anaphylactic or severe allergic reactions - Elevated liver enzymes or hepatic dysfunction

Before prescribing Kogrel, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

Assess bleeding risk: review history of ulcers, surgery or coagulopathy. Monitor platelet function: consider laboratory testing in high‑risk individuals. Avoid use in active pathological bleeding: discontinue if significant bleeding occurs. Caution in hepatic impairment: adjust therapy based on liver function. Store at below 25°C: keep in the original pack, protect from moisture.

Clopidogrel may interact with several drug classes, altering bleeding risk or antiplatelet efficacy.

Major Interactions (Avoid): - Concurrent oral anticoagulants (warfarin, DOACs): markedly increased bleeding risk. - NSAIDs (ibuprofen, naproxen): heightened gastrointestinal bleeding. - Proton pump inhibitors (omeprazole): possible reduction in clopidogrel activation.

Moderate Interactions (Monitor Closely): - CYP2C19 inhibitors (fluoxetine, fluconazole): may raise clopidogrel plasma levels. - CYP2C19 inducers (rifampin, carbamazepine): may diminish antiplatelet effect. - SSRIs (sertraline, fluoxetine): additive bleeding tendency.